Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer
(MedPage Today) -- MADRID -- Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was seen in PD-L1-negative... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 21, 2023 Category: Hematology Source Type: news
Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity
(MedPage Today) -- A four-drug regimen for newly diagnosed high-risk multiple myeloma induced high rates of sustained minimal residual disease (MRD) negativity regardless of transplant status, a German research group reported.
Two-thirds of transplant... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 19, 2023 Category: Hematology Source Type: news
Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment
(MedPage Today) -- People living alone have a higher risk of cancer mortality. (Cancer)
Integrating an automated screening tool into an electronic health record system showed potential for identifying patients for cancer clinical trials. (Cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 19, 2023 Category: Hematology Source Type: news
Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A
(MedPage Today) -- Early emicizumab (Hemlibra) prophylaxis alone prevented clinically relevant bleeds in patients with newly diagnosed acquired hemophilia A, while avoiding the infectious complications of immunosuppressive therapy in this vulnerable... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 19, 2023 Category: Hematology Source Type: news
Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train?
(MedPage Today) -- Come December, as I observe my "pros-mitzvah" -- 13 years on active surveillance (AS) for very low-risk prostate cancer -- I feel I'm at a tipping point.
Should I stay the course and keep monitoring my lesion -- a single... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 18, 2023 Category: Hematology Source Type: news
Pembrolizumab Wins FDA Approval in Operable Lung Cancer
(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) on Monday in combination with platinum-based chemotherapy for the perioperative treatment of resectable non-small cell lung cancer (NSCLC).
Approval was based on improved event-free... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 17, 2023 Category: Hematology Source Type: news
Hemoglobin Targets a Good Idea for Massively Transfused Patients
(MedPage Today) -- SAN FRANCISCO -- Critically ill patients receiving blood transfusions of 10 or more units had substantially better survival when it brought hemoglobin levels close to normal, according to a single-center study reported here... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 16, 2023 Category: Hematology Source Type: news
Study Validates Accuracy of PREDICT Prognostication Tool in Breast Cancer
(MedPage Today) -- The PREDICT prognostication tool was able to estimate overall survival (OS) with decent accuracy in a large independent U.S. dataset of breast cancer patients, researchers reported.
From more than 700,000 patients in the National... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 13, 2023 Category: Hematology Source Type: news
Cryoprecipitate, REBOA Flop for Improving Major Hemorrhage Outcomes
(MedPage Today) -- Two newer approaches to management of major hemorrhage missed the mark in randomized clinical trials published in a special transfusion-related issue of JAMA.
In the CRYOSTAT-2 trial, adding early, high-dose cryoprecipitate... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 13, 2023 Category: Hematology Source Type: news
Hair Relaxers' Cancer Risk; Genetic Test Aids Rural Care; Drug Negotiation Fallout?
(MedPage Today) -- Regular use of chemical hair relaxers by Black women increased their risk of uterine cancer by 50%. (Boston University, Environmental Research)
Adding the immune activator BXCL701 to pembrolizumab (Keytruda) significantly improved... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 13, 2023 Category: Hematology Source Type: news
Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC
(MedPage Today) -- The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on Wednesday.
The approval was... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 12, 2023 Category: Hematology Source Type: news
HER3-Targeted Drug Active in Advanced/Metastatic Breast Cancer
(MedPage Today) -- An antibody-drug conjugate (ADC) targeting HER3 produced objective responses in as many as 43% of patients with advanced breast cancer, a prospective clinical trial showed.
Responses to patritumab deruxtecan (HER3-DXd) occurred... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 10, 2023 Category: Hematology Source Type: news
How a Multi-Cancer Screening Test Would Play Out in the Clinic
(MedPage Today) -- Confirming an actual cancer diagnosis in patients flagged as potentially having a malignancy by a multicancer blood test typically required multiple imaging scans and laboratory tests, suggested results from PATHFINDER, a prospective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 10, 2023 Category: Hematology Source Type: news
Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Live
(MedPage Today) -- The shortage of crucial cancer drugs has eased a bit, but the vast majority of cancer centers are still "living paycheck to paycheck." (STAT)
Final results from a large clinical trial showed that a multicancer early detection... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 6, 2023 Category: Hematology Source Type: news
Bladder-Sparing Neoadjuvant Protocol Gets High Marks for MIBC
(MedPage Today) -- More than 40% of patients with muscle-invasive bladder cancer (MIBC) avoided immediate cystectomy after achieving a clinical complete response (cCR) with a chemoimmunotherapy combination, a prospective study showed.
Overall... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 6, 2023 Category: Hematology Source Type: news
